文献速递胸部肿瘤放疗

低剂量SBRT放疗序贯帕博利珠单抗联合化疗用于潜在可切除非小细胞肺癌的1b期研究

Low-Dose Stereotactic Body Radiation Therapy-Based Radiation Therapy Followed by Pembrolizumab and Chemotherapy for Potentially Resectable Non-Small Cell Lung Cancer: A Phase 1b Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-06-09

这项1b期研究评估了潜在可切除III期NSCLC患者接受新辅助低剂量SBRT为基础放疗后序贯帕博利珠单抗联合化疗的安全性和手术转化率。中位随访22.8个月时,中位无进展生存期29.0个月,中位总生存期37.9个月。

要点

  • 新辅助低剂量SBRT序贯帕博利珠单抗联合化疗在潜在可切除III期NSCLC中耐受性可接受。
  • 手术转化率64.7%,R0切除率90.9%,病理完全缓解率54.5%。
  • 中位PFS 29.0个月,中位OS 37.9个月,需注意1例5级手术相关肺动脉出血事件。

核心结论

  • 新辅助低剂量SBRT为基础放疗序贯帕博利珠单抗联合化疗在潜在可切除III期NSCLC中可耐受,并显示出有前景的手术转化率和病理缓解率。

研究设计与样本

  • 1b期研究,纳入 multidisciplinary team 评估为潜在可切除的III期NSCLC患者,接受新辅助低剂量SBRT为基础放疗(周围病灶24 Gy、中央病灶12 Gy,分3次)后序贯2周期帕博利珠单抗100 mg联合铂类化疗。
  • 主要终点为安全性,次要终点包括病理完全缓解、无进展生存期和总生存期。

主要发现

  • 全程3-5级治疗相关不良事件5例(29.4%),最常见为3级白细胞减少2例(11.8%),包括1例因致命性肺动脉出血导致的5级手术事件。
  • 客观缓解16例(94.1%),手术成功11例(64.7%),其中10例(90.9%)实现R0切除,6例(54.5%)达到病理完全缓解。
  • 中位随访22.8个月(95% CI,18.9-26.7),中位无进展生存期29.0个月(95% CI,18.1-39.9),中位总生存期37.9个月(95% CI,21.9-53.9)。

关键数值与推荐

  • 周围病灶SBRT剂量24 Gy,中央病灶12 Gy,均分3次照射。
  • 帕博利珠单抗剂量100 mg,联合铂类化疗,共2周期。
  • 新辅助治疗后4-6周由第二 multidisciplinary team 评估手术可行性。

临床怎么用

  • 该方案可作为潜在可切除III期NSCLC的新辅助治疗选择之一,但需多学科团队评估手术可行性并警惕严重手术相关不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Chemoradiation therapy is standard for unresectable stage III non-small cell lung cancer (NSCLC). This phase 1b study assessed the safety and surgical conversion of neoadjuvant low-dose stereotactic body radiation therapy (SBRT)-based radiation therapy followed by pembrolizumab and chemotherapy in patients with potentially resectable stage III NSCLC. METHODS AND MATERIALS: Patients deemed potentially resectable by the multidisciplinary team received neoadjuvant low-dose SBRT-based radiation therapy to the primary tumor (24 Gy for peripheral lesions and 12 Gy for central lesions) delivered in 3 fractions. Selective planning target volumes were applied to spare critical structures and optimize surgical safety. Two cycles of 100-mg pembrolizumab plus platinum-based chemotherapy followed. Surgical feasibility was evaluated by the second multidisciplinary team 4 to 6 weeks after neoadjuvant therapy. The primary endpoint was safety; secondary endpoints included pathological complete response, progression-free survival, and overall survival. RESULTS: Seventeen patients received neoadjuvant therapy, with no dose-limiting toxicities observed. Across the overall treatment course, grade 3 to 5 treatment-related adverse events were reported in 5 patients (29.4%), most commonly grade 3 leukopenia (2 patients, 11.8%), and included 1 grade 5 surgical event due to fatal pulmonary artery hemorrhage. Objective responses were noted in 16 patients (94.1%). Surgery was successfully conducted in 11 patients (64.7%), with 10 (90.9%) achieving R0 resection. Six patients (54.5%) achieved pathological complete response. At a median follow-up of 22.8 months (95% CI, 18.9-26.7), the median progression-free survival was 29.0 months (95% CI, 18.1-39.9), and median overall survival was 37.9 months (95%CI, 21.9-53.9). CONCLUSIONS: Neoadjuvant low-dose SBRT-based radiation therapy followed by pembrolizumab and chemotherapy is tolerable and demonstrates promising rates of surgical conversion and pathological response in patients with potentially resectable stage III NSCLC.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Zhu X, Zhao L, Zhang S, et al. Low-Dose Stereotactic Body Radiation Therapy-Based Radiation Therapy Followed by Pembrolizumab and Chemotherapy for Potentially Resectable Non-Small Cell Lung Cancer: A Phase 1b Study. Int J Radiat Oncol Biol Phys. 2026. PMID: 42264097. doi:10.1016/j.ijrobp.2026.05.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。